Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Sustained release dosage forms for a JAK1 inhibitor

Sustained release dosage forms for a JAK1 inhibitor

US Patent 12151026 · Granted Nov 26, 2024

Estimated economic value: $37,065,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dosing regimen for the treatment of PI3K related disorders2025
Topical formulation for a JAK inhibitor2025
Topical formulation for a JAK inhibitor2025
JAK1 pathway inhibitors for the treatment of gastrointestinal disease2024
Sustained-release dosage forms of ruxolitinib2024
Sustained-release dosage forms of ruxolitinib2024
Methods of treating cancer with an FGFR inhibitor2023
JAK1 pathway inhibitors for the treatment of gastrointestinal disease2023
Topical formulation for a JAK inhibitor2023
Topical formulation for a JAK inhibitor2023
Sustained-release dosage forms of ruxolitinib2023
Sustained-release dosage forms of ruxolitinib2023